Travere Therapeutics (TVTX) Free Cash Flow (2011 - 2026)
Travere Therapeutics (TVTX) posted Free Cash Flow of -$40.4 million for Q1 2026, down 166.52% on a QoQ basis from $60.7 million in Q4 2025, and up 4.33% year-over-year from -$38.7 million in Q1 2025.
Travere Therapeutics (TVTX) Free Cash Flow (2011 - 2026) Analysis & Trends
Travere Therapeutics' Free Cash Flow history runs 16 years deep, the most recent figure standing at -$40.4 million for Q1 2026.
- Quarterly Free Cash Flow rose 4.33% year-over-year to -$40.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.5 million (up 124.54% YoY) and the FY2025 annual result came in at $37.8 million, up 115.91% from the prior year.
- Free Cash Flow was -$40.4 million for Q1 2026 at Travere Therapeutics, down from $60.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $60.7 million in Q4 2025 and bottomed at -$118.9 million in Q1 2024.
- A 5-year average of -$44.3 million and a median of -$42.1 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow plunged 675.99% — and 2025, when it surged 268.17%.
- Travere Therapeutics' Free Cash Flow stood at -$54.7 million in 2022, then sank by 111.88% to -$115.8 million in 2023, then surged by 68.85% to -$36.1 million in 2024, then jumped by 268.17% to $60.7 million in 2025, then tumbled by 166.52% to -$40.4 million in 2026.
- Business Quant data shows TVTX's Free Cash Flow at -$40.4 million in Q1 2026, $60.7 million in Q4 2025, and $14.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | -40.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.37 Mn |
| Mar 31, 2026 | -40.37 Mn |
| Dec 31, 2025 | 60.68 Mn |
| Dec 31, 2025 | 60.68 Mn |
| Sep 30, 2025 | 14.18 Mn |
| Sep 30, 2025 | 14.18 Mn |
| Jun 30, 2025 | 4.98 Mn |
| Jun 30, 2025 | 4.98 Mn |
| Mar 31, 2025 | -42.19 Mn |
| Mar 31, 2025 | -42.19 Mn |
| Dec 31, 2024 | -36.08 Mn |
| Dec 31, 2024 | -36.08 Mn |
| Sep 30, 2024 | -42.15 Mn |
| Sep 30, 2024 | -42.15 Mn |
| Jun 30, 2024 | -40.43 Mn |
| Jun 30, 2024 | -40.43 Mn |
| Mar 31, 2024 | -118.90 Mn |
| Mar 31, 2024 | -118.90 Mn |
| Dec 31, 2023 | -115.83 Mn |
| Dec 31, 2023 | -115.83 Mn |